A breast cancer drug lapatinib (Tykerb, by GlaxoSmithKline pharmaceutical manufacturers) When used with capecitabine (Xeloda, Roche pharmaceutical manufacturers) and for receiving trastuzumab (Herceptin cancer Ping He, Genentech / Roche pharmaceutical manufacturers) in the treatment of the failure of HER2 receptor positive women's breast cancer, the use of lapatinib will be able to extend the time for patients whose condition had deteriorated to Tatsu 2 times.
The trial results are published in the December 28, 2006 --- the best medical journal New England Journal of Medicine, the trial received a 324 belonging to He Ping cancer treatment failure of the HER2 receptor positive breast cancer patients, the initial Research results have been published in the 2006 American Society of Clinical Oncology annual meeting, due to very positive results, the independent data monitoring committee early termination of the vendor-sponsored tests.
U.S. Food and Drug Administration (FDA) in March 2007 end of the breast cancer drug Tykerb approved the listing of the end of suffering from malignant breast cancer, other treatments can not be suppressed to provide a new choice for women.
HER2 overexpression for the suffering of patients with advanced or metastatic breast cancer, He Ping is already the standard of cancer treatment, the current proposal is He Ping cancer with chemotherapy. However, epithelial growth factor receptor (EGFR) over-performance of the treatment of patients with breast cancer associated with poor prognosis, but also, and He Ping cancer treatment failure very well. Therefore, overexpression of the HER2 receptor positive cells, at the same time inhibit EGFR and HER2, is additive effect. Lapatinib is an oral tyrosine kinase inhibitors, is a kind of role can be in the EGFR and HER2. 17.5% of patients taking lapatinib will happen a third-class diarrhea. Other third-tier side effects include skin rashes, fatigue
, Nausea, anorexia, vomiting, but the incidence of less than 10%.
No comments:
Post a Comment